These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
449 related articles for article (PubMed ID: 15604239)
21. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth. Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735 [TBL] [Abstract][Full Text] [Related]
22. Immune responses of mice to vaccinia virus recombinants expressing either Listeria monocytogenes partial listeriolysin or Brucella abortus ribosomal L7/L12 protein. Baloglu S; Boyle SM; Vemulapalli R; Sriranganathan N; Schurig GG; Toth TE Vet Microbiol; 2005 Aug; 109(1-2):11-7. PubMed ID: 15941627 [TBL] [Abstract][Full Text] [Related]
23. High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action. Kim SH; Castro F; Paterson Y; Gravekamp C Cancer Res; 2009 Jul; 69(14):5860-6. PubMed ID: 19584282 [TBL] [Abstract][Full Text] [Related]
24. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Hung CF; Hsu KF; Cheng WF; Chai CY; He L; Ling M; Wu TC Cancer Res; 2001 Feb; 61(3):1080-8. PubMed ID: 11221836 [TBL] [Abstract][Full Text] [Related]
25. Role of listeriolysin-O (LLO) in the T lymphocyte response to infection with Listeria monocytogenes. Identification of T cell epitopes of LLO. Safley SA; Cluff CW; Marshall NE; Ziegler HK J Immunol; 1991 May; 146(10):3604-16. PubMed ID: 1709197 [TBL] [Abstract][Full Text] [Related]
27. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Hsieh CJ; Kim TW; Hung CF; Juang J; Moniz M; Boyd DA; He L; Chen PJ; Chen CH; Wu TC Vaccine; 2004 Sep; 22(29-30):3993-4001. PubMed ID: 15364449 [TBL] [Abstract][Full Text] [Related]
28. Listeriolysin O-deficient Listeria monocytogenes as a vaccine delivery vehicle: antigen-specific CD8 T cell priming and protective immunity. Hamilton SE; Badovinac VP; Khanolkar A; Harty JT J Immunol; 2006 Sep; 177(6):4012-20. PubMed ID: 16951364 [TBL] [Abstract][Full Text] [Related]
29. A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8 Li J; Chen S; Ge J; Lu F; Ren S; Zhao Z; Pu X; Chen X; Sun J; Gu Y Vaccine; 2017 Nov; 35(47):6459-6467. PubMed ID: 29029939 [TBL] [Abstract][Full Text] [Related]
30. Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene. Cheng WF; Hung CF; Chai CY; Hsu KF; He L; Rice CM; Ling M; Wu TC J Immunol; 2001 May; 166(10):6218-26. PubMed ID: 11342644 [TBL] [Abstract][Full Text] [Related]
31. An in silico DNA vaccine against Listeria monocytogenes. Jahangiri A; Rasooli I; Gargari SL; Owlia P; Rahbar MR; Amani J; Khalili S Vaccine; 2011 Sep; 29(40):6948-58. PubMed ID: 21791233 [TBL] [Abstract][Full Text] [Related]
32. Immunological responses and anti-tumor effects of HPV16/18 L1-L2-E7 multiepitope fusion construct along with curcumin and nanocurcumin in C57BL/6 mouse model. Kayyal M; Bolhassani A; Noormohammadi Z; Sadeghizadeh M Life Sci; 2021 Nov; 285():119945. PubMed ID: 34516991 [TBL] [Abstract][Full Text] [Related]
33. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation. Seo SH; Jin HT; Park SH; Youn JI; Sung YC Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174 [TBL] [Abstract][Full Text] [Related]
34. Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine. Sewell DA; Douven D; Pan ZK; Rodriguez A; Paterson Y Arch Otolaryngol Head Neck Surg; 2004 Jan; 130(1):92-7. PubMed ID: 14732776 [TBL] [Abstract][Full Text] [Related]
35. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Hung CF; Cheng WF; Hsu KF; Chai CY; He L; Ling M; Wu TC Cancer Res; 2001 May; 61(9):3698-703. PubMed ID: 11325841 [TBL] [Abstract][Full Text] [Related]
36. Adenovirus-based vaccine against Listeria monocytogenes: extending the concept of invariant chain linkage. Jensen S; Steffensen MA; Jensen BA; Schlüter D; Christensen JP; Thomsen AR J Immunol; 2013 Oct; 191(8):4152-64. PubMed ID: 24043891 [TBL] [Abstract][Full Text] [Related]
38. What is needed for effective antitumor immunotherapy? Lessons learned using Listeria monocytogenes as a live vector for HPV-associated tumors. Hussain SF; Paterson Y Cancer Immunol Immunother; 2005 Jun; 54(6):577-86. PubMed ID: 15650885 [TBL] [Abstract][Full Text] [Related]
39. Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice. Peng S; Trimble C; He L; Tsai YC; Lin CT; Boyd DA; Pardoll D; Hung CF; Wu TC Gene Ther; 2006 Jan; 13(1):67-77. PubMed ID: 16107858 [TBL] [Abstract][Full Text] [Related]
40. Cytolysin-dependent escape of the bacterium from the phagosome is required but not sufficient for induction of the Th1 immune response against Listeria monocytogenes infection: distinct role of Listeriolysin O determined by cytolysin gene replacement. Hara H; Kawamura I; Nomura T; Tominaga T; Tsuchiya K; Mitsuyama M Infect Immun; 2007 Aug; 75(8):3791-801. PubMed ID: 17517863 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]